Why the study?
Does BiDil reduce mortality in African-Americans with heart failure?
Does BiDil reduce mortality in African-Americans with heart failure?
The African-American Heart Failure Trial demonstrates that race can be a useful, albeit imprecise, marker for identifying population differences in treatment effects, highlighting the need for personalized medicine.
No takes yet. Share an insight, caveat, or question.
May inform race-stratified HF prescribing; leaves open validation of more precise biomarkers beyond race.
Jay N. Cohn (2006) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: